Setareh Samimi

560 total citations
8 papers, 77 citations indexed

About

Setareh Samimi is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, Setareh Samimi has authored 8 papers receiving a total of 77 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 3 papers in Pathology and Forensic Medicine and 2 papers in Cancer Research. Recurrent topics in Setareh Samimi's work include Colorectal Cancer Treatments and Studies (4 papers), Genetic factors in colorectal cancer (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Setareh Samimi is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Genetic factors in colorectal cancer (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Setareh Samimi collaborates with scholars based in Canada and United States. Setareh Samimi's co-authors include Scott R. Berry, Petr Kavan, John R. Goffin, Félix Couture, Chaudhary E. Ahmad, F. Aubin, Sheryl Koski, Derek J. Jonker, Mohammed Harb and Benoît Samson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Treatment Reviews and Cancer Medicine.

In The Last Decade

Setareh Samimi

8 papers receiving 75 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Setareh Samimi Canada	4	72	30	17	13	10	8	77
Vincenzo Guarini Italy	3	56 0.8×	25 0.8×	10 0.6×	19 1.5×	19 1.9×	4	69
Chaudhary E. Ahmad Canada	2	54 0.8×	24 0.8×	12 0.7×	7 0.5×	6 0.6×	5	56
Maria Kuiper Netherlands	3	86 1.2×	38 1.3×	21 1.2×	12 0.9×	40 4.0×	5	104
J. Martin-Babau France	6	67 0.9×	21 0.7×	8 0.5×	10 0.8×	25 2.5×	20	86
Jill Weiss United States	4	56 0.8×	33 1.1×	34 2.0×	5 0.4×	15 1.5×	8	72
Ana-Maria Mușină Romania	5	57 0.8×	17 0.6×	13 0.8×	15 1.2×	6 0.6×	11	79
Cosimo Rasola Italy	7	88 1.2×	48 1.6×	39 2.3×	37 2.8×	26 2.6×	16	118
Andrew Kedziora Australia	4	66 0.9×	45 1.5×	22 1.3×	5 0.4×	12 1.2×	4	103
John Hrom United States	6	47 0.7×	20 0.7×	25 1.5×	12 0.9×	11 1.1×	15	78

Countries citing papers authored by Setareh Samimi

Since Specialization

Citations

This map shows the geographic impact of Setareh Samimi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Setareh Samimi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Setareh Samimi more than expected).

Fields of papers citing papers by Setareh Samimi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Setareh Samimi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Setareh Samimi. The network helps show where Setareh Samimi may publish in the future.

Co-authorship network of co-authors of Setareh Samimi

This figure shows the co-authorship network connecting the top 25 collaborators of Setareh Samimi. A scholar is included among the top collaborators of Setareh Samimi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Setareh Samimi. Setareh Samimi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Wong, Jason K., Howard J. Lim, Vincent C. Tam, et al.. (2023). Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. Cancer Treatment Reviews. 115. 102526–102526. 3 indexed citations

Loree, Jonathan M., Derek J. Jonker, Hagen F. Kennecke, et al.. (2023). Plasma phosphocreatine (PC) as a predictive biomarker for immune checkpoint inhibition in patients with refractory metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial.. Journal of Clinical Oncology. 41(4_suppl). 183–183. 1 indexed citations

Cuthbert, Colleen, Nancy Nixon, Michael M. Vickers, et al.. (2022). Top 10 research priorities for early-stage colorectal cancer: a Canadian patient-oriented priority-setting partnership. CMAJ Open. 10(1). E278–E287. 3 indexed citations

Chen, Eric Xueyu, Jonathan M. Loree, Dongsheng Tu, et al.. (2022). Effects of liver metastases on efficacy of immune checkpoint blockade in treatment refractory, metastatic colorectal cancer (CRC): CCTG CO.26.. Journal of Clinical Oncology. 40(16_suppl). 3600–3600. 1 indexed citations

Samimi, Setareh, Quan Hong, James E. J. Bedard, et al.. (2020). Evaluating the impact of universal Lynch syndrome screening in a publicly funded healthcare system. Cancer Medicine. 9(18). 6507–6514. 4 indexed citations

Chen, Eric Xueyu, Derek J. Jonker, Hagen F. Kennecke, et al.. (2019). CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).. Journal of Clinical Oncology. 37(4_suppl). 481–481. 37 indexed citations

Chen, Eric Xueyu, Derek J. Jonker, Jonathan M. Loree, et al.. (2019). CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).. Journal of Clinical Oncology. 37(15_suppl). 3512–3512. 17 indexed citations

Kalloger, Steve E., Maziar Riazy, Basile Tessier‐Cloutier, et al.. (2017). A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine. The Journal of Pathology Clinical Research. 3(3). 179–190. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact